[Adriamycin--breast cancer]

The significance of doxorubicin (ADR) was reviewed in the treatment of advanced as well as early breast cancer. The history of ADR treatment, mainly as a combination of CAF, or FAC, has revealed that ADR is still the key drug for breast cancer, the response rate being 40-60%. A multivariate analysis in 182 advanced breast cancer cases showed that the predictive factor was the dominant site of metastasis, and performance status (PS). Overall survival was determined with the age, the dominant site of metastasis, and PS. Recently the combination chemotherapy including ADR was evaluated to be equivalent to CMF type chemotherapy in the adjuvant settings.